# Trading Cycle Report - 2026-05-30 (Cycle 2)

**Environment**: staging
**Cycle triggered**: manual via `POST http://agents-service:8000/api/trigger-cycle` at 12:41:54 UTC (second cycle of the day; the first was the scheduled 06:48 UTC cycle covered in `TRADING_CYCLE_REPORT_20260530.md`)
**Total cycle duration**: 2m 27s (12:41:54 → 12:44:22)
**Overall result**: 4/4 completed, 3 trades executed (1 HOLD), 0 failed
**Deployment context**: Cycle run immediately after the at-deploy staging push of all components, which propagated the recent submodule refactor where `TradingRunService` is wired via `RunEventPublisher` + `RunDtoMapper` + `RunSpecificationFactory`, and `TradingAgent.setInitialCapital(...)` is part of the constructor flow.

---

## Cycle Summary (12:41 UTC)

| Agent  | Style              | Decision | Symbol | Qty | Price    | Total       | Candidates                  |
|--------|--------------------|----------|--------|-----|----------|-------------|-----------------------------|
| George | Contrarian Macro   | BUY      | SCCO   | 37  | $191.30  | $7,078.10   | ASML, PLTR, SCCO            |
| Ray    | Risk Parity        | SELL     | PG     | 44  | $143.56  | $6,316.64   | KO, MCD, KMB, O             |
| Warren | Value Investor     | HOLD     | —      | —   | —        | —           | CSCO, IBM, PEP              |
| Cathie | Growth Innovation  | SELL     | PATH   | 670 | $11.72   | $7,852.40   | BEAM, CRSP, COIN, ISRG      |

---

## Portfolio Snapshots (Latest)

| Agent  | Cash         | Holdings Value | Total Value   | Total P&L     | Return %   |
|--------|--------------|----------------|---------------|---------------|------------|
| Warren | $34,194.01   | $76,839.04     | $111,033.05   | +$11,033.05   | +11.03%    |
| George | $28,573.99   | $75,990.95     | $104,564.94   | +$4,564.94    | +4.56%     |
| Ray    | $42,164.34   | $54,808.01     | $96,972.35    | −$3,027.65    | −3.03%     |
| Cathie | $31,076.51   | $97,480.38     | $128,556.89   | +$28,556.89   | +28.56%    |
| **Combined** | **$136,008.85** | **$305,118.38** | **$441,127.23** | **+$41,127.23** | **+10.28%** |

### Current Holdings

**Warren (account_id=1)** — 10 positions: ADP, BRK.B, JNJ, MCD, MRK, MSFT, ORCL, PG, UNP, V

**George (account_id=2)** — 10 positions: CCJ, FNV, GOLD, MP, MU, RTX, SCCO, UEC, XOM, ZIM

**Ray (account_id=3)** — 9 positions: ADP, ATO, CVX, ITW, JNJ, MDT, TRV, VZ, WM

**Cathie (account_id=4)** — 9 positions: AMD, ARM, ASML, GOOGL, MSFT, NVDA, PLTR, SNOW, TSLA

---

## Detailed Run Data

### Run 529: George (Contrarian Macro) — BUY SCCO

**Started**: 12:41:54 UTC | **Completed**: 12:43:12 UTC (~1m 18s) | **Status**: COMPLETED

#### Research Phase (46,421ms)
**Candidates**: ASML, PLTR, SCCO

**Tool Calls** (6):
1. `brave_web_search(query="Southern Copper macro outlook 2026 copper supply deficit 2026 Reuters", count=5)`
2. `brave_web_search(query="ASML demand 2026 semiconductor equipment AI capex 2026 Bloomberg Reuters ASML outlook 2026", count=5)`
3. `brave_web_search(query="Palantir earnings 2026 government revenue secular growth contrarian thesis 2026 Reuters Bloomberg May 2026 Palantir", count=5)`
4. `lookup_price_tool(symbol="ASML")`
5. `lookup_price_tool(symbol="PLTR")`
6. `lookup_price_tool(symbol="SCCO")`

**Research Notes**:
> Macro-driven, contrarian shortlist: 1) ASML — secular AI-driven chip-equipment demand has outpaced consensus; capacity tightness presents asymmetric upside if AI capex continues, making ASML a high-conviction way to play a structural shift in semi supply chains. 2) Palantir (PLTR) — market skepticism on software multiples contrasts with accelerating government and commercial adoption of AI analytics; recent guidance upgrades show improving fundamentals while sentiment remains mixed. 3) Southern Copper (SCCO) — copper supply disruptions and projected deficits into 2026 create a contrarian commodity exposure with strong demand tailwinds from electrification/EVs.
>
> These picks fit George's macro/contrarian profile: asymmetric upside from structural technology and commodity dislocations, currency-insensitive large-cap names (ASML, SCCO ADR-like exposure through NY listing), and a sentiment-discounted software play tied to geopolitics and AI spending (PLTR).

**Web Sources**:
- [ASML lifts 2026 forecast as surging AI chip demand boosts new orders — Reuters](https://www.reuters.com/business/asml-lifts-2026-outlook-back-stronger-ai-demand-2026-04-15/)
- [ASML lifts outlook on record AI chip orders but analysts query capacity — Reuters](https://www.reuters.com/business/asml-q4-bookings-beat-expectations-chipmakers-order-more-satisfy-ai-demand-2026-01-28/)
- [Palantir tops first-quarter revenue estimates on strong US government demand — Reuters](https://www.reuters.com/business/palantir-tops-first-quarter-revenue-estimates-strong-us-government-demand-2026-05-04/)
- [Palantir Reports Q1 2026 U.S. Revenue Growth of 104% Y/Y — Investor release](https://investors.palantir.com/news-details/2026/Palantir-Reports-Q1-2026-U-S--Revenue-Growth-of-104-YY-and-Revenue-Growth-of-85-YY-Raises-FY-2026-Revenue-Guidance-to-71-YY-Growth-and-U-S--Comm-Revenue-Guidance-to-120-YY-Crushing-Consensus-Expectations/)
- [Slower production growth will push copper market to deficit in 2026 — Reuters](https://www.reuters.com/business/slower-production-growth-will-push-copper-market-deficit-2026-says-icsg-2025-10-08/)
- [Copper to hold gains in 2026 as mine disruptions fuel deficit — Reuters](https://www.reuters.com/business/copper-hold-gains-2026-mine-disruptions-fuel-deficit-2025-10-27/)

**Portfolio Context**: Balance $35,652.09, 9 positions (XOM, FNV, MU, UEC, GOLD, RTX, MP, ZIM, CCJ)

#### Decision Phase (23,842ms)
**Decision**: BUY SCCO × 37 @ $191.30

**Reasoning**:
- **Rationale**: Buy Southern Copper (SCCO) to capture asymmetric upside from a multi-year copper deficit driven by supply disruptions and electrification demand; valuation and sentiment remain less consensus-crowded than ASML and offer clearer commodity reflexivity than PLTR's software re-rating.
- **Research**: Market Analyst candidates considered: (1) ASML — price $1,612.76; widely owned, elevated multiples (public P/Es cited mid-30s→~50s) though Reuters notes stronger 2026 outlook and capacity tightness. (2) PLTR — price $156.54; mixed sentiment despite accelerating adoption and strong guidance (U.S. revenue +104% Y/Y). (3) SCCO — price $191.30; analyst screens cite TTM P/E ≈28.7 and multiple Reuters/ICSG pieces point to copper deficits into 2026. I prefer SCCO over ASML because ASML is consensus-owned with rich valuation limiting contrarian asymmetry despite supply tightness; I prefer SCCO over PLTR because SCCO provides direct commodity reflexivity to a clear structural supply/demand dislocation (asymmetric upside if deficits persist) and fits portfolio sizing/budget constraints (deployable ~$7.08k ≤ $7.13k cap).
- **Portfolio**: Cash $35,652.09; positions 9/10. This adds SCCO as the 10th position, deploying $7,078.10 (37 × $191.30) — within the $7,130.42 single-position cap and available cash — increasing commodity exposure (copper) to complement existing miners/energy holdings while keeping diversification limits intact.
- **Historical**: Recent mixed activity in SCCO: buys on 2026-04-27 (25 @ $180.43) and 2026-05-07 (33 @ $183.84) and sells on 2026-05-02 (25 @ $171.18) and 2026-05-09 (33 @ $185.31), indicating prior conviction with tactical trimming; trade history shows a pattern of buying dips and trimming into strength.

**Decision Tool Calls** (1):
1. `get_symbol_trade_history(symbol="SCCO")`

#### Execution
**Trade #426**: BUY 37 shares SCCO @ $191.30 = $7,078.10 — account_id=2 (George)

---

### Run 530: Ray (Risk Parity) — SELL PG

**Started**: 12:41:55 UTC | **Completed**: 12:43:29 UTC (~1m 34s) | **Status**: COMPLETED

#### Research Phase (55,056ms)
**Candidates**: KO, MCD, KMB, O

**Tool Calls** (10):
1. `brave_web_search(query="dividend aristocrats list Coca-Cola McDonald's Kimberly-Clark Colgate Realty Income beta dividend yield Yahoo Finance 2026", count=10)`
2. `brave_web_search(query="KO Yahoo Finance quote Coca-Cola Co. KO beta dividend yield Yahoo Finance", count=5)`
3. `brave_web_search(query="MCD Yahoo Finance McDonald's MCD stock quote beta dividend yield Yahoo Finance", count=5)`
4. `brave_web_search(query="KMB Yahoo Finance Kimberly-Clark KMB stock quote beta dividend yield Yahoo Finance", count=5)`
5. `brave_web_search(query="Realty Income O Yahoo Finance O stock quote beta dividend yield Realty Income dividend monthly Yahoo Finance", count=5)`
6. `lookup_price_tool(symbol="KO")`
7. `lookup_price_tool(symbol="MCD")`
8. `lookup_price_tool(symbol="KMB")`
9. `lookup_price_tool(symbol="O")`
10. `fetch(url="https://finance.yahoo.com/quote/KO/", max_length=4000)`

**Research Notes**:
> I screened for low-beta, high-quality, dividend-paying names that add defensive, low-correlation exposure to an already-industrial/healthcare/energy-heavy portfolio. Recommended candidates are classic dividend aristocrats (KO, KMB, MCD) for recession resilience and steady income, plus Realty Income (O) to add REIT exposure and an inflation-sensitive income stream. Each candidate has a long dividend history, low volatility relative to the market, and sector diversification value for a risk-parity/all-weather allocation.

**Web Sources**:
- [The Coca-Cola Company (KO) Stock Price, News, Quote & History — Yahoo Finance](https://finance.yahoo.com/quote/KO/)
- [McDonald's Corporation (MCD) Stock Price, News, Quote & History — Yahoo Finance](https://finance.yahoo.com/quote/MCD/)
- [Kimberly-Clark Corporation (KMB) Stock Price, News, Quote & History — Yahoo Finance](https://finance.yahoo.com/quote/KMB/)
- [Realty Income Corporation (O) Stock Price, News, Quote & History — Yahoo Finance](https://finance.yahoo.com/quote/O/)
- [Dividend Aristocrats in a Shaky Market: KO, PG, JNJ, and 2 Others Built to Last — Yahoo Finance](https://finance.yahoo.com/news/dividend-aristocrats-shaky-market-ko-130211889.html)
- [2026 Dividend Aristocrats List: All 69 Ranked & Analyzed — Simply Safe Dividends](https://www.simplysafedividends.com/world-of-dividends/posts/6-2025-dividend-aristocrats-list-all-69-ranked-analyzed)

**Portfolio Context**: Balance $35,847.70, 10 positions (WM, ITW, CVX, VZ, ATO, PG, TRV, MDT, JNJ, ADP)

#### Decision Phase (32,728ms)
**Decision**: SELL PG × 44 @ $143.56

**Reasoning**:
- **Rationale**: Sell the full PG position to reduce consumer-staples concentration and free the 10th slot so we can add a lower-correlation income sleeve (preferably Realty Income O) on the next cycle.
- **Research**: Market Analyst candidates: KO (price $79.01; P/E typically mid-20s; stable dividend); MCD (price $279.20; P/E mid-20s; durable franchise); KMB (price $97.60; trailing P/E low-teens ≈13-16; higher yield); O (price $61.28; REIT with monthly, inflation-sensitive income). PG itself trades around P/E ≈20-21 (overlaps staples exposure). Selling PG removes overlap with KO/MCD/KMB and creates capacity to add O, which offers lower correlation to our industrial/energy/healthcare sleeves and a distinct inflation-sensitive income stream — improving portfolio diversification and risk-adjusted resilience under the risk-parity framework.
- **Portfolio**: Cash $35,847.70; positions 10/10 (WM, ITW, CVX, VZ, ATO, PG, TRV, MDT, JNJ, ADP). Selling 44 PG shares clears one position slot and raises cash to fund a new position sized within the per-position cap ($5,377.16) while preserving risk-parity balance across industrials/energy/healthcare income sleeves.
- **Historical**: get_symbol_trade_history shows PG is an accumulating/rotating position: 5 trades in the past 90 days (3 buys, 2 sells), current 44 shares @ avg cost $142.24 — recent churn and prior buys/sells indicate reduced conviction and a clean exit with limited turnover impact.

**Decision Tool Calls** (1):
1. `get_symbol_trade_history(symbol="PG")`

#### Execution
**Trade #428**: SELL 44 shares PG @ $143.56 = $6,316.64 — account_id=3 (Ray)

---

### Run 531: Warren (Value Investor) — HOLD

**Started**: 12:41:55 UTC | **Completed**: 12:44:22 UTC (~2m 27s) | **Status**: COMPLETED

#### Research Phase (80,087ms)
**Candidates**: CSCO, IBM, PEP

**Tool Calls** (9):
1. `brave_web_search(query="May 2026 undervalued value stocks Cisco IBM PepsiCo Chevron P/E ROE free cash flow 2026", count=10)`
2. `brave_web_search(query="Cisco Systems CSCO P/E ROE free cash flow May 2026 Reuters Yahoo Finance CSCO valuation", count=5)`
3. `brave_web_search(query="IBM valuation P/E ROE debt-to-equity free cash flow May 2026 Reuters Yahoo Finance IBM key statistics", count=5)`
4. `brave_web_search(query="PepsiCo PEP valuation P/E ROE debt-to-equity free cash flow May 2026 Yahoo Finance Reuters PepsiCo key statistics", count=5)`
5. `brave_web_search(query="Chevron CVX valuation P/E ROE debt-to-equity free cash flow May 2026 Yahoo Finance Reuters CVX key statistics", count=5)`
6. `lookup_price_tool(symbol="CSCO")`
7. `lookup_price_tool(symbol="IBM")`
8. `lookup_price_tool(symbol="PEP")`
9. `lookup_price_tool(symbol="CVX")`

**Research Notes**:
> I screened for durable-moat, cash-generative U.S. names trading at modest valuations versus peers and identified three candidates that align with a long-term value approach. Cisco (CSCO) offers a wide networking moat, recurring software/serving contracts and steady free cash flow with a lower absolute valuation versus high-growth peers. IBM (IBM) combines a sticky enterprise software/services franchise (hybrid cloud/AI) with improving margins and strong ROE metrics driven by higher-margin software revenue. PepsiCo (PEP) is a consumer-staples stalwart with leading brands, consistent earnings and free cash flow, strong return on capital, and shareholder-friendly capital allocation.
>
> Each candidate complements the current portfolio by adding undervalued, cash-generative franchises that historically return capital to shareholders. Given the portfolio is at capacity, these picks are presented as replacements to consider (see portfolio_context) rather than additions; the focus is selecting high-quality businesses trading at reasonable multiples with durable competitive advantages and solid free cash flow profiles.

**Web Sources**:
- [Cisco Systems, Inc. (CSCO) Valuation Measures & Financial Statistics — Yahoo Finance](https://finance.yahoo.com/quote/CSCO/key-statistics/)
- [Cisco Systems Reported Lower FCF and Margins — Has CSCO Stock Peaked? — Yahoo Finance](https://finance.yahoo.com/markets/stocks/articles/cisco-systems-reported-lower-fcf-133002755.html)
- [International Business Machines Corporation (IBM) Valuation Measures & Financial Statistics — Yahoo Finance](https://finance.yahoo.com/quote/IBM/key-statistics/)
- [International Business Machines (IBM) Statistics & Valuation — StockAnalysis](https://stockanalysis.com/stocks/ibm/statistics/)
- [PepsiCo, Inc. (PEP) Valuation Measures & Financial Statistics — Yahoo Finance](https://finance.yahoo.com/quote/PEP/key-statistics/)
- [PepsiCo (PEP) Statistics & Valuation — StockAnalysis](https://stockanalysis.com/stocks/pep/statistics/)

**Portfolio Context**: Balance $34,194.01, 10 positions (BRK.B, ORCL, PG, MSFT, JNJ, MCD, ADP, MRK, UNP, V)

#### Decision Phase (60,101ms)
**Decision**: HOLD

**Reasoning**:
- **Rationale**: Portfolio is at the 10-position limit and none of the three candidates offers a clear margin-of-safety improvement versus incumbents (PEP overlaps existing staples; IBM carries execution/leverage risk despite mid-20s multiples; CSCO has been traded round-trip in this account), so I will wait for a decisive dislocation or a defendable sell candidate.
- **Research**: Market Analyst candidates reviewed: CSCO (price $120.42) — cited by analyst as lower absolute valuation vs high-growth peers but account trade history shows churn. IBM (price $297.80) — sticky enterprise software/hybrid-cloud franchise with improving margins; analyst notes trailing/forward P/Es in the low-20s. PEP (price $144.19) — durable consumer staples compounder with consistent FCF and a trailing P/E in the mid-20s per the analyst. None of the three displaces an incumbent on a clear margin-of-safety basis (PEP would increase staples overlap with PG/MCD; IBM's valuation relies on execution; CSCO has been recently traded), so HOLD aligns with my long-term, value-first discipline while I watch for a clearer opportunity.
- **Portfolio**: Cash $34,194.01; positions 10/10 (BRK.B, ORCL, PG, MSFT, JNJ, MCD, ADP, MRK, UNP, V). Cannot open a new slot without selling; per-position cap $5,129.10 would limit any new position size. Given capacity and sizing constraints, HOLD preserves optionality while monitoring valuations and catalysts.
- **Historical**: CSCO shows repeated short-term round-trips in this account in May 2026 (multiple buys and sells between ~$87-$120), indicating lower conviction in a replacement role; IBM and PEP are not currently held in this account and have no recent trade history here.

**Decision Tool Calls** (1):
1. `get_symbol_trade_history(symbol="CSCO")`

#### Execution
**No execution phase** — HOLD decision, no trade row created (correct contract).

---

### Run 532: Cathie (Growth Innovation) — SELL PATH

**Started**: 12:41:55 UTC | **Completed**: 12:43:24 UTC (~1m 29s) | **Status**: COMPLETED

#### Research Phase (57,446ms)
**Candidates**: BEAM, CRSP, COIN, ISRG

**Tool Calls** (8):
1. `brave_web_search(query="Beam Therapeutics 2026 base editing R&D 2026 news Beam Therapeutics revenue growth 2025 2026 BEAM", count=5)`
2. `brave_web_search(query="CRISPR Therapeutics 2026 pipeline revenue 2025 CRSP R&D 2026 news exa gene editing 2026 Q1 2026 press release", count=5)`
3. `brave_web_search(query="Coinbase 2026 growth crypto exchange 2026 results revenue 2025 2026 institutional trading growth Coinbase 2026 news", count=5)`
4. `brave_web_search(query="Intuitive Surgical 2026 robotics growth da Vinci surgical systems 2026 revenue growth R&D 2025 2026 news Intuitive Surgical Q1 2026 results", count=5)`
5. `lookup_price_tool(symbol="BEAM")`
6. `lookup_price_tool(symbol="CRSP")`
7. `lookup_price_tool(symbol="COIN")`
8. `lookup_price_tool(symbol="ISRG")`

**Research Notes**:
> I screened for disruptive innovators across genomics, AI-driven fintech, and surgical robotics that match a Cathie-style, long-horizon growth mandate. Beam Therapeutics (BEAM) is a base-editing leader with accelerating collaboration revenue and heavy R&D investment to build a platform for broad therapeutic applications. CRISPR Therapeutics (CRSP) offers near-term commercial exposure (CASGEVY) and a broader gene-editing pipeline positioning it for multi-billion TAM capture if clinical milestones succeed. Coinbase (COIN) is a leading crypto infrastructure and exchange platform benefiting from expanding institutional products and improving topline growth as crypto adoption and derivatives volumes rise. Intuitive Surgical (ISRG) is the dominant surgical-robotics franchise with double-digit procedure growth, accelerating system placements, and strong cash flow to fuel R&D and ecosystem expansion.
>
> Given the portfolio is full (10 positions), these candidates are presented as high-conviction additions to consider when rotating positions: BEAM and CRSP add differentiated exposure to next-generation gene editing (high R&D, binary clinical catalysts); COIN adds fintech/blockchain infrastructure exposure that complements existing software and platform holdings; ISRG provides a lower-volatility, high-innovation play in robotics/medtech with recurring consumable revenue and margin expansion potential.

**Web Sources**:
- [Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates](https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-reports-first-quarter-2026-financial-results)
- [Beam Therapeutics: Building the Rails for the Base Editing Paradigm Shift — AInvest](https://www.ainvest.com/news/beam-therapeutics-building-rails-base-editing-paradigm-shift-2601/)
- [CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-first-7)
- [CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-highlights-strategic-priorities-and-0/)
- [Coinbase Q1 Financial Results Show Resilient Financial Performance](https://investor.coinbase.com/news/news-details/2026/Coinbase-Q1-Financial-Results-Show-Resilient-Financial-Performance-Driven-by-New-All-Time-High-Crypto-Trading-Volume-Market-Share/default.aspx)
- [Crypto market predictions for 2026: Coinbase Institutional highlights the next big things — CoinDesk](https://www.coindesk.com/markets/2025/12/28/coinbase-says-three-areas-will-dominate-the-crypto-market-in-2026)
- [Intuitive Announces First Quarter Earnings — Intuitive Surgical](https://isrg.intuitive.com/news-releases/news-release-details/intuitive-announces-first-quarter-earnings-7)
- [Intuitive Surgical lifts 2026 outlook for da Vinci robot procedure growth — MedTech Dive](https://www.medtechdive.com/news/intuitive-surgical-lifts-2026-outlook-for-da-vinci-robot-procedure-growth/818193/)

**Portfolio Context**: Balance $23,224.11, 10 positions (NVDA, AMD, PATH, GOOGL, PLTR, ASML, SNOW, TSLA, ARM, MSFT)

#### Decision Phase (25,033ms)
**Decision**: SELL PATH × 670 @ $11.72

**Reasoning**:
- **Rationale**: Trim a churned, overlapping software holding to create capacity for a higher-conviction, lower-volatility innovation exposure (Intuitive Surgical) identified by the Market Analyst.
- **Research**: Market Analyst candidates: BEAM ($32.93) — base editing leader with heavy R&D and binary clinical risk; CRSP ($56.18) — CRISPR with early CASGEVY commercial revenue but biotech binary/regulatory exposure; COIN ($189.03) — crypto exchange/infra with cyclicality and elevated forward P/E (~53.9 cited by Analyst); ISRG ($424.64) — dominant surgical-robotics franchise with recurring consumable revenue, double-digit procedure growth and stronger cash flow to fund R&D. I sell PATH because it is redundant with existing software/platform exposure and has shown trading churn, whereas ISRG offers portfolio diversification into durable medical robotics with lower single-binary risk than BEAM/CRSP and less regulatory/volume cyclicality than COIN (ISRG forward P/E cited in mid-40s by the Analyst).
- **Portfolio**: Current cash $23,224.11, positions 10/10. Selling entire PATH (670 shares) frees a slot and meaningful cash to redeploy into a surgical-robotics/medtech leader (ISRG) that diversifies away from heavy compute/software concentration (NVDA/GOOGL/MSFT) while staying within the 25% per-position sizing cap when we execute the future buy.
- **Historical**: PATH shows frequent trading and position churn in the last 90 days (multiple buy/sell cycles; current position 670 shares, avg cost ~$10.68), indicating lower conviction vs. longer-horizon platform/compute holdings; enterprise automation overlaps existing cloud/platform exposure.

**Decision Tool Calls** (1):
1. `get_symbol_trade_history(symbol="PATH")`

#### Execution
**Trade #427**: SELL 670 shares PATH @ $11.72 = $7,852.40 — account_id=4 (Cathie)

---

## Aggregate Statistics

| Metric | Value |
|--------|-------|
| Total Runs | 4 |
| Successful | 4 (100%) |
| Failed | 0 |
| Total Trades | 3 (1 BUY, 2 SELL) |
| HOLD Decisions | 1 (Warren) |
| Capital Deployed (BUY) | $7,078.10 |
| Capital Returned (SELL) | $14,169.04 |
| Net Cash Change | +$7,090.94 |
| Avg Research Latency | 59,752 ms |
| Avg Decision Latency | 35,426 ms |
| Total Research Tool Calls | 33 (8.25 avg/run) |
| Total Decision Tool Calls | 4 |
| Combined Portfolio Value | $441,127.23 |
| Combined P&L | +$41,127.23 |
| Combined Return | +10.28% (on $400K seed) |

---

## Comparison with Previous Report

**Previous**: TRADING_CYCLE_REPORT_20260530.md (cycle at 06:48 UTC — first cycle of the day, on the same Track 2B build)
**Current**: TRADING_CYCLE_REPORT_20260530_2.md (cycle at 12:41 UTC — manual second cycle of the day after the at-deploy push)

| Metric | Previous (06:48 UTC) | Current (12:41 UTC) | Status |
|--------|-----------------------|-----------------------|--------|
| Completion Rate | 4/4 (100%) | 4/4 (100%) | ✅ OK |
| Trades Executed | 3 (1 HOLD) | 3 (1 HOLD) | ✅ OK |
| HOLD Decisions | 1 | 1 (Warren both cycles) | ✅ OK |
| Failed Runs | 0 | 0 | ✅ OK |
| Reasoning Fields Complete | 4/4 | 4/4 | ✅ OK |
| Missing Phases | 0 | 0 | ✅ OK |
| Cycle Duration | 2m 10s | 2m 27s | ✅ OK (within LLM variance) |
| Combined Portfolio Value (snapshot) | n/a (covered in that report) | $441,127.23 | — |

### Per-agent comparison (Snapshot vs. 2-cycle-earlier 2026-05-29 baseline)

The previous report (`TRADING_CYCLE_REPORT_20260530.md`) covers the 06:48 UTC cycle on the same Track 2B build, so the structural metrics are essentially flat. The portfolio-value drift is more meaningfully read against the previous-day report (`TRADING_CYCLE_REPORT_20260529.md`):

| Agent | 2026-05-29 Total | 2026-05-30 (cycle 2) Total | Δ Total | Δ % |
|---|---:|---:|---:|---:|
| Warren | $110,728.26 | $111,033.05 | +$304.79 | +0.28% |
| George | $104,605.52 | $104,564.94 | −$40.58 | −0.04% |
| Ray | $97,673.27 | $96,972.35 | −$700.92 | −0.72% |
| Cathie | $127,862.53 | $128,556.89 | +$694.36 | +0.54% |
| **Combined** | **$440,869.58** | **$441,127.23** | **+$257.65** | **+0.06%** |

### Regressions Found

**None.** The new service-decomposition wiring (`RunEventPublisher` / `RunDtoMapper` / `RunSpecificationFactory`) exercised end-to-end without behavioral change:

- **All 4 runs completed** with full research, decision, and execution phases persisted.
- **3 trades persisted** into `trading.account_transactions` (IDs 426, 427, 428) with correct symbol, quantity, price, total_amount, and account linkage.
- **Warren's HOLD correctly produced no execution_phase row and no transaction** — verified via the execution-phase query returning only 3 entries (runs 529, 530, 532), not 4. HOLD contract preserved.
- **All decision reasoning fields populated** (`rationale`, `researchContext`, `portfolioContext`, `historicalContext`) for all 4 runs, including the HOLD.
- **All `get_symbol_trade_history` MemoryService tool calls returned populated history** — visible in every run's historical reasoning (SCCO accumulation pattern; PG churn; CSCO round-trips; PATH high-frequency turnover).
- **Backend rollout from the at-deploy push** completed cleanly with no critical errors in the deployment log scan.

### Notable behavioral observations (model, not system)

1. **Cathie's PATH round-trip closed at +$93.80.** Yesterday's report (2026-05-29) flagged Cathie's PATH BUY at $11.58 as a likely round-trip in the open follow-ups. This cycle she sold the same 670 PATH at $11.72 — exactly the predicted pattern. Phase C's MemoryService served her the prior 90-day churn history in the reasoning text, and the LLM cited it explicitly ("PATH shows frequent trading and position churn... avg cost ~$10.68") before still choosing to exit. *Memory wired correctly; the model still favors high-turnover trading in this name.*
2. **Warren HOLD'd for the same structural reason both cycles today.** Both the 06:48 cycle (in the sibling report) and this 12:41 cycle had Warren return HOLD with portfolio-at-capacity + no clear margin-of-safety language. Stable value-investor discipline.
3. **Ray executed yesterday's plan.** Yesterday: SELL T to free a defensive-sleeve slot. Today (intermediate cycle 525-528 visible in the sibling report): added VZ. This cycle: SELL PG with stated plan to add Realty Income (O) next. Continues the slow multi-cycle defensive-sleeve rotation pattern.
4. **George returned to commodity exposure.** Yesterday: BUY WFC (financials diversification). Today (in the earlier intermediate cycle, visible in the sibling report): added MU. This cycle: BUY SCCO (more copper). Book is now 10/10 with 8 commodity/extractive names — diversification narrative inconsistent across cycles.

### System-health verdict

✅ **Staging is healthy end-to-end after the at-deploy push and the RunEventPublisher/RunDtoMapper/RunSpecificationFactory refactor.**

- All 4 services rolled cleanly (frontend HTTP 200, market API cache flip false→true confirmed both before and after this cycle).
- New service-decomposition wiring exercised through the full pipeline (createRun → updatePhase × N → completeRun) without errors.
- Database state matches the contract: 3 execution_phase rows for 3 trades, 1 HOLD with no execution row, 0 nulls in reasoning fields.
- The 7-day public-display delay on `/api/runs` is still intentional — dashboard sees fresh runs via the admin path.

---

## Open follow-ups

1. **Decision latency on HOLD** — Warren's HOLD took 60.1 s vs the typical 20-30 s for clear BUY/SELL decisions. Both cycles today had Warren HOLD with similar elevated decision latency. If HOLD becomes Warren's default state, this is worth a closer look — the model deliberates longer when no candidate clearly wins, which is correct behavior but adds wall-clock.
2. **Cathie's PATH round-trip prediction was correct** — yesterday's report explicitly predicted this would happen. Closed at +$93.80 net, so no economic harm, but it is now a documented same-symbol churn pattern alongside her earlier SNOW churn (3 reversals across 26-27 May). Worth considering a same-symbol cool-down prompt constraint.
3. **George's commodity drift continues** — three of his last four cycles have added or kept commodity/extractive exposure. His "contrarian macro" mandate keeps proposing financials and software but he keeps picking the commodity option. Not a system issue, but the diversification thesis is being eroded by his own picks.
4. **Production parity** — prod is still on the build from the previous cycle (without the new RunEventPublisher / RunDtoMapper / RunSpecificationFactory wiring). Staging is now ahead by this refactor. Once you're satisfied with this cycle's evidence, `at-deploy all production` would propagate it.
